Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 533-541

  Lebrec, Didier ^a,b   Bosch, Jaime ^c   Jalan, Rajiv ^d   Dudley, Francis J ^e   Jessic, Rada ^f   Moreau, Richard ^a,b   Garcia Pagan, Juan Carlos ^c   Mookerjee, Rajeshwar P ^d   Chiossi, Eleonora ^g   Van Giersbergen, Paul L M ^g   Kusic Pajic, Andjela ^g   Dingemanse, Jasper ^g  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b BEAUJON HOSPITAL   (France)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f Institute for Digestive Diseases   (Serbia)

^g ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Cirrhosis; Endothelin receptor antagonist; Pharmacodynamics; Pharmacokinetics; Portal hypertension; Tezosentan

Indexed keywords

ENDOTHELIN 1; PLACEBO; TEZOSENTAN;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTERIAL PRESSURE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART RATE; HUMAN; HYPOTENSION; KIDNEY DISEASE; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER VEIN; MALE; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPLANCHNIC BLOOD FLOW; STEADY STATE; SYSTEMIC CIRCULATION; VEIN INJURY; VENOUS PRESSURE;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; INFUSIONS, PARENTERAL; LIVER; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIDINES; RECEPTORS, ENDOTHELIN; SEVERITY OF ILLNESS INDEX; SPLANCHNIC CIRCULATION; TETRAZOLES; VASODILATOR AGENTS;

EID: 84864280028     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1157-6     Document Type: Article

References (32)

1. Iwakiri Y, Grisham M, Shah V (2008) Vascular biology and pathobiology of the liver: report of a single-topic symposium. Hepatology 47:1754-1763 (Pubitemid 351702757)
2. Rockey D (1997) The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 25:2-5 (Pubitemid 27014976)
3. Yanagisawa M, Kurihara H, Kimura Y, Tomobe Y, Kobayashi M, Mitsui Y et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415 (Pubitemid 18090241)
4. Moore K, Wendon J, Frazer M, Karami J, Williams R, Badr K et al (1992) Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774-1778
5. Uchihara M, Izumi N, Sato C, Marumo F (1992) Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 16:95-99
6. Hartleb M, Kirstetter P, Moreau R, Soupison T, Pussard E, Hadengue A et al (1994) Relations entre les concentrations plasmatiques d'endotheline et la severite de la cirrhose. Gastroenterol Clin Biol 18:407-412 (Pubitemid 24223089)
7. Salo J, Francitorra A, Follo A, Navasa M, Ginès A, Jiménez W et al (1995) Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. J Hepatol 22:389-398
8. Moller S, Gülberg V, Henriksen JH, Gerbes AL (1995) Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 23:135-144
9. Bernardi M, Gülberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL (1996) Plasma endothelin-1 and-3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 24:161-168 (Pubitemid 26057952)
10. B receptor antagonist, in portal hypertensive rats. Hepatology 28:655-659 (Pubitemid 28405411)
11. Reichen J, Gerbes AL, Steiner MJ, Sägesser A, Clozel M (1998) The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic liver. J Hepatol 28:1020-1030 (Pubitemid 28275982)
12. Rockey DC, Weisiger RA (1996) Endothelin-induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24:233-240 (Pubitemid 26249439)
13. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Löffler BM et al (1999) Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290:840-846 (Pubitemid 29344584)
14. Dingemanse J, Clozel M, van Giersbergen PLM (2002) Entryinto-human study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol 39:795-802 (Pubitemid 34538809)
15. Treiber A, van Giersbergen PLM, Dingemanse J (2003) In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans. Xenobiotica 33:399-414 (Pubitemid 36688116)
16. Dingemanse J, Halabi A, van Giersbergen PLM (2009) Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. J Clin Pharmacol 49:455-464
17. Lebrec D, Sogni P, Vilgrain V (1997) Evaluation of patients with portal hypertension. Clin Gastroenterol 11:221-241 (Pubitemid 27460184)
18. Bosch J, Navasa M, Garcia-Pagan JC, DeLacy AM, Rodes J (1989) Portal hypertension. Med Clin North Am 73:931-953 (Pubitemid 19163732)
19. Burns E, Triger DR, Tucker GT, Bax ND (1991) Indocyanine green elimination in patients with liver disease and in normal subjects. Clin Sci 80:155-160
20. Gadano A, Hadengue A, Vachiery F, Moreau R, Sogni P, Soupison T et al (1997) Relationship between hepatic blood flow, liver tests, haemodynamic values and clinical characteristics in patients with chronic liver disease. J Gastroenterol Hepatol 12:167-171 (Pubitemid 27096390)
21. Van Giersbergen PL, Wipfli P, Dingemanse J (2003) Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 792:369-373 (Pubitemid 36830887)
22. Dorr MB, Pollack GM (1989) Specific assay for the quantitation of indocyanine green in rat plasma using high-performance liquid chromatography with fluorescence detection. J Pharm Sci 78:328-333 (Pubitemid 19171930)
23. Keiding S, Vilstrup H (2002) Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. Scand J Gastroenterol 37:960-964 (Pubitemid 34969932)
24. Valla D, Bercoff E, Menu Y, Bataille C, Lebrec D (1984) Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterol 86:1400-1403 (Pubitemid 14147929)
25. Dingemanse J, van Giersbergen PLM (2004) Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. Br J Clin Pharmacol 57:344-348 (Pubitemid 38296998)
26. Dingemanse J, Gunawardena KA, van Giersbergen PL (2006) Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjects. Br J Clin Pharmacol 61:405-413
27. Parker JD, Thiessen JJ, Reilly R, Tong JH, Stewart DJ, Pardey AS (1999) Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther 289:261-265 (Pubitemid 29156038)
28. Dupuis J, Steward DJ, Cernacek P, Gosselin G (1996) Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94:1578-1584 (Pubitemid 26320261)
29. Burkhardt M, Barton M, Shaw SG (2000) Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade. J Hypertension 18:273-279 (Pubitemid 30142843)
30. Meijer DKF, Weert B, Vermeer GA (1988) Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur J Clin Pharmacol 35:295-303
31. Soons PA, Kroon JM, Breimer DD (1990) Effects of single-dose and short-term oral nifedipine on indocyanine green clearance as assessed by spectrophotometry and high performance liquid chromatography. J Clin Pharmacol 30:693-698 (Pubitemid 20324617)
32. Navasa M, Chesta J, Bosch J, Rodes J (1989) Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 96:1110-1118 (Pubitemid 19091127)